Last reviewed · How we verify
Ioversol 320 mgI/mL
Ioversol is a non-ionic, iodinated contrast medium that increases radiodensity in blood vessels and tissues to enhance visualization during radiographic imaging procedures.
Ioversol is a non-ionic, iodinated contrast medium that increases radiodensity in blood vessels and tissues to enhance visualization during radiographic imaging procedures. Used for Contrast enhancement for coronary angiography and cardiac imaging, Contrast enhancement for peripheral vascular angiography, Contrast enhancement for cerebral angiography.
At a glance
| Generic name | Ioversol 320 mgI/mL |
|---|---|
| Also known as | Optiray |
| Sponsor | Guerbet |
| Drug class | Non-ionic iodinated contrast medium |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | FDA-approved |
Mechanism of action
Ioversol contains iodine atoms that absorb X-rays more strongly than surrounding soft tissues, creating contrast that allows radiologists to visualize vascular structures, organs, and pathology on X-ray and CT imaging. The non-ionic formulation reduces osmolality compared to ionic contrast agents, which decreases the risk of adverse reactions and renal toxicity. It is administered intravenously and distributes throughout the intravascular and extracellular compartments before being renally eliminated.
Approved indications
- Contrast enhancement for coronary angiography and cardiac imaging
- Contrast enhancement for peripheral vascular angiography
- Contrast enhancement for cerebral angiography
- Contrast enhancement for CT imaging of the abdomen, pelvis, and thorax
Common side effects
- Contrast-induced nephropathy (acute kidney injury)
- Allergic reaction (rash, urticaria)
- Anaphylaxis
- Nausea and vomiting
- Flushing and warmth sensation
- Hypotension
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ioversol 320 mgI/mL CI brief — competitive landscape report
- Ioversol 320 mgI/mL updates RSS · CI watch RSS
- Guerbet portfolio CI